Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

New agents for sickle cell disease: patient perceptions of benefit in the real world

Robert T Means
DOI: 10.1136/jim-2022-002464 Published 22 June 2022
Robert T Means
Internal Medicine and Pathology, James H Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert T Means
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Sickle cell disease (SCD) is one of the most important monogeneic diseases in the world, causing significant morbidity and mortality and consuming substantial healthcare resources.1 SCD results from a single amino acid substitution in the β-globin chain, leading to sickle hemoglobin (HbS). In oxygen-limited settings, HbS forms polymers that lead to the characteristic sickle-shaped erythrocytes and also to changes in the erythrocyte membrane. The pathological features of SCD result from a combination of vaso-occlusive events precipitated both by abnormal erythrocyte morphology and the increased expression of adhesion molecules on its outer membrane; accelerated hemolysis that can deplete nitric oxide and that leads to anemia; and a high level of endogenous inflammatory activation associated with repeated ischemia/reperfusion cycles, themselves precipitated by vaso-occlusion.2

Hydroxyurea, the first-line and indeed only approved therapy for SCD for some 20 years, was approved in 1998.3 Hydroxyurea upregulates δ-globin production, increasing intracellular levels of hemoglobin F which in turn decreases polymerization of HbS. Hydroxyurea therapy decreases the frequency of painful vaso-occlusive crises, blood transfusions, and hospital admissions.4

However, there are factors that result in underutilization of hydroxyurea in SCD.5 Although frequently prescribed, there is a high incidence of discontinuation due to side effects (24.6% in one recent report4) but also due to patient perception of ineffectiveness (16.4%4). In the last few years, three new agents have been approved for the treatment of SCD, each of which addresses a different element of SCD pathophysiology6: L-glutamine, which reduces oxidative stress in SCD by increasing erythrocyte nicotinamide adenine levels; crizanlizumab, a competitive inhibitor of P-selectin that decreases sickle erythrocyte adhesion during vaso-oclusive crises; and voxelotor, which increases hemoglobin oxygen affinity and prevents HbS polymerization.7 8

In a paper in this issue of JIM, Idowu and colleagues discuss patient perception of the treatment benefit for 23 consecutive patients with SCD (21 homozygous SCD (HbSS), 2 sickle-β0 thalassemia) received from voxelotor.9 All had significant ongoing hemolysis resulting in anemia and had evidence of organ dysfunction. They were evaluated using two separate scales that assessed the global impression of change in patient status from the perspective of the clinician and of the patient, respectively. Most patients reported a perception of substantial clinical improvement. Interestingly, this did not correlate entirely with the changes in hemoglobin concentration, since some patients reported improvement with stable or even worsened anemia, although most patients had evidence of improved hemoglobin concentrations and decreased hemolysis.

This study did not include patients who were unable to have voxelotor covered by a payer. This is a significant challenge in patients treated with new agents: in another recent real-world cohort study of voxelotor in SCD, approximately one-third of patients for whom it was prescribed never took voxelotor, due to problems completing required paperwork (41%), disapproval by insurance (18%), or high copays (5%).10

Studies like this report by Idowu and colleagues advance clinical practice by recognizing the importance of the perceptions of the two primary partners in patient care: the clinicians and the patients themselves.

Ethics statements

Patient consent for publication

Not required.

Ethics approval

Not applicable.

Footnotes

  • Contributors RTM is the sole contributor of this work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests RTM is an Associate Editor for the Journal of Investigate Medicine. No other competing interests declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

References

  1. ↵
    1. Lanzkron S ,
    2. Little J ,
    3. Field J , et al
    . Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv 2018;2:2412–7.doi:10.1182/bloodadvances.2018018382 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30254105
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Ware RE ,
    2. de Montalembert M ,
    3. Tshilolo L , et al
    . Sickle cell disease. Lancet 2017;390:311–23.doi:10.1016/S0140-6736(17)30193-9 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28159390
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ault A
    . US FDA approves first drug for sickle-cell anaemia. Lancet 1998;351:809.doi:10.1016/S0140-6736(05)78941-8
    OpenUrlPubMed
  4. ↵
    1. Bradford C ,
    2. Miodownik H ,
    3. Thomas M , et al
    . Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. Am J Hematol 2022;97:E93–5.doi:10.1002/ajh.26438 pmid:http://www.ncbi.nlm.nih.gov/pubmed/34914130
    OpenUrlPubMed
  5. ↵
    1. Lanzkron S ,
    2. Haywood C ,
    3. Fagan PJ , et al
    . Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved 2010;21:277–86.doi:10.1353/hpu.0.0272 pmid:http://www.ncbi.nlm.nih.gov/pubmed/20173269
    OpenUrlPubMed
  6. ↵
    1. Ali MA ,
    2. Ahmad A ,
    3. Chaudry H , et al
    . Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol 2020;92:11–18.doi:10.1016/j.exphem.2020.08.008 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32841705
    OpenUrlPubMed
  7. ↵
    1. Vichinsky E ,
    2. Hoppe CC ,
    3. Ataga KI , et al
    . A phase 3 randomized trial of Voxelotor in sickle cell disease. N Engl J Med 2019;381:509–19.doi:10.1056/NEJMoa1903212 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31199090
    OpenUrlPubMed
  8. ↵
    1. Howard J ,
    2. Ataga KI ,
    3. Brown RC , et al
    . Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2021;8:e323–33.doi:10.1016/S2352-3026(21)00059-4
    OpenUrlPubMed
  9. ↵
    1. Idowu M ,
    2. Haque A ,
    3. Williams EA , et al
    . Patient perception of voxelotor treatment benefit in sickle cell disease. J Investig Med 2022;70:1316–9.doi:10.1136/jim-2021-002215
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Curtis SA ,
    2. Betancourt J ,
    3. Kottapalli N , et al
    . Voxelotor use in adults with sickle cell disease in a real‐world setting. Am J Hematol 2022;97:E125–8.doi:10.1002/ajh.26453
    OpenUrl
PreviousNext
Back to top
Vol 70 Issue 5 Table of Contents
Journal of Investigative Medicine: 70 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New agents for sickle cell disease: patient perceptions of benefit in the real world
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
New agents for sickle cell disease: patient perceptions of benefit in the real world
Robert T Means
Journal of Investigative Medicine Jun 2022, 70 (5) 1210-1211; DOI: 10.1136/jim-2022-002464

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
New agents for sickle cell disease: patient perceptions of benefit in the real world
Robert T Means
Journal of Investigative Medicine Jun 2022, 70 (5) 1210-1211; DOI: 10.1136/jim-2022-002464
Download PDF

Share
New agents for sickle cell disease: patient perceptions of benefit in the real world
Robert T Means
Journal of Investigative Medicine Jun 2022, 70 (5) 1210-1211; DOI: 10.1136/jim-2022-002464
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Ethics statements
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Saying goodbye and remembering
  • COVID-19 vaccine efficacy in a rapidly changing landscape
Show more Editorial

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research